CU20150144A7 - Derivados de imidazo-triazina como inhibidores de la pde 10 - Google Patents

Derivados de imidazo-triazina como inhibidores de la pde 10

Info

Publication number
CU20150144A7
CU20150144A7 CUP2015000144A CU20150144A CU20150144A7 CU 20150144 A7 CU20150144 A7 CU 20150144A7 CU P2015000144 A CUP2015000144 A CU P2015000144A CU 20150144 A CU20150144 A CU 20150144A CU 20150144 A7 CU20150144 A7 CU 20150144A7
Authority
CU
Cuba
Prior art keywords
pde
inhibitors
triazine derivatives
imidazo
camp
Prior art date
Application number
CUP2015000144A
Other languages
English (en)
Spanish (es)
Inventor
Thomas Allen Chappie
Christopher John Helal
Bethany Lyn Kormos
Jamison Bryce Tuttle
Patrick Robert Verhoest
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CU20150144A7 publication Critical patent/CU20150144A7/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CUP2015000144A 2013-05-02 2015-10-19 Derivados de imidazo-triazina como inhibidores de la pde 10 CU20150144A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361818650P 2013-05-02 2013-05-02
PCT/IB2014/060945 WO2014177977A1 (en) 2013-05-02 2014-04-23 Imidazo-triazine derivatives as pde10 inhibitors

Publications (1)

Publication Number Publication Date
CU20150144A7 true CU20150144A7 (es) 2016-04-25

Family

ID=50841902

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2015000144A CU20150144A7 (es) 2013-05-02 2015-10-19 Derivados de imidazo-triazina como inhibidores de la pde 10

Country Status (33)

Country Link
US (3) US8933224B2 (OSRAM)
EP (1) EP2991989B1 (OSRAM)
JP (1) JP6263606B2 (OSRAM)
KR (1) KR101770905B1 (OSRAM)
CN (1) CN105164134B (OSRAM)
AP (1) AP2015008843A0 (OSRAM)
AR (1) AR096161A1 (OSRAM)
AU (1) AU2014261070A1 (OSRAM)
BR (1) BR112015027760A8 (OSRAM)
CA (1) CA2910759C (OSRAM)
CL (1) CL2015003037A1 (OSRAM)
CR (1) CR20150591A (OSRAM)
CU (1) CU20150144A7 (OSRAM)
DK (1) DK2991989T3 (OSRAM)
DO (1) DOP2015000271A (OSRAM)
EA (1) EA027936B1 (OSRAM)
EC (1) ECSP15050110A (OSRAM)
ES (1) ES2637816T3 (OSRAM)
GE (1) GEP201706675B (OSRAM)
MA (1) MA38559B1 (OSRAM)
MD (1) MD20150103A2 (OSRAM)
MX (1) MX2015015163A (OSRAM)
NI (1) NI201500157A (OSRAM)
NZ (1) NZ712949A (OSRAM)
PE (1) PE20151940A1 (OSRAM)
PH (1) PH12015502462A1 (OSRAM)
SG (1) SG11201508201VA (OSRAM)
TN (1) TN2015000490A1 (OSRAM)
TW (1) TWI508966B (OSRAM)
UA (1) UA111696C2 (OSRAM)
UY (1) UY35547A (OSRAM)
WO (1) WO2014177977A1 (OSRAM)
ZA (1) ZA201508968B (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ712949A (en) * 2013-05-02 2017-04-28 Pfizer Imidazo-triazine derivatives as pde10 inhibitors
WO2018047081A1 (en) 2016-09-09 2018-03-15 Novartis Ag Compounds and compositions as inhibitors of endosomal toll-like receptors
US12448374B2 (en) 2018-06-07 2025-10-21 Disarm Therapeutics, Inc. Inhibitors of SARM1
EP3897670A4 (en) 2018-12-19 2022-09-07 Disarm Therapeutics, Inc. MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS
MX2022004741A (es) * 2019-10-21 2022-05-16 Sk Biopharmaceuticals Co Ltd Uso de compuestos de imidazopirimidina o imidazotriazina para prevencion, alivio, o tratamiento de trastornos cognitivos, o para mejorar la funcion cognitiva.
CN117486878A (zh) * 2023-10-27 2024-02-02 扬州市普林斯医药科技有限公司 一种恩那司他的制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010007867A1 (en) 1999-12-13 2001-07-12 Yuhpyng L. Chen Substituted 6,5-hetero-bicyclic derivatives
DE10130167A1 (de) 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
DE10230604A1 (de) 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
JP2007508241A (ja) 2003-07-31 2007-04-05 バイエル・フアーマシユーチカルズ・コーポレーシヨン Pde10a阻害剤を用いる糖尿病および関連障害の処置方法
JP4559749B2 (ja) * 2004-02-16 2010-10-13 あすか製薬株式会社 ピペラジニルピリジン誘導体
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
US20070167426A1 (en) 2004-06-02 2007-07-19 Schering Corporation Compounds for the treatment of inflammatory disorders and microbial diseases
TW200716102A (en) 2005-06-01 2007-05-01 Wyeth Corp Bicyclic 6-alkylidene-penems as class-D β -lactamases inhibitors
US20080051419A1 (en) 2006-07-26 2008-02-28 Pfizer Inc. Amine derivatives useful as anticancer agents
WO2008041571A1 (en) 2006-09-26 2008-04-10 Kaneka Corporation Process for producing optically active beta-hydroxy-alpha-aminocarboxylic acid ester
WO2008057402A2 (en) 2006-11-02 2008-05-15 Cytovia, Inc. N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof
EP2203171A2 (en) 2007-08-21 2010-07-07 Merck Sharp & Dohme Corp. Cb2 receptor ligands for the treatment of pain
DE102007059723A1 (de) 2007-12-12 2009-06-18 Siemens Medical Instruments Pte. Ltd. Hörvorrichtung mit Batterieklappenmodul
TWI431010B (zh) 2007-12-19 2014-03-21 Lilly Co Eli 礦皮質素受體拮抗劑及使用方法
MX2010010151A (es) 2008-03-20 2010-10-25 Amgen Inc Moduladores de cinasa aurora y metodo de uso.
EP2493889B1 (en) * 2009-10-30 2017-09-06 Janssen Pharmaceutica, N.V. IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
EP2526102B1 (en) 2010-01-22 2017-03-08 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Inhibitors of PI3 kinase
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
US20130131057A1 (en) 2010-05-13 2013-05-23 Centro Nacional De Investigaciones Oncologicas (Cnio New bicyclic compounds as pi3-k and mtor inhibitors
BR112012029994A2 (pt) 2010-05-28 2019-09-24 Biocryst Pharm Inc composto heterocíclicos como inibidores de janus quinase
US20130085161A1 (en) 2010-06-17 2013-04-04 Novartis Ag Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
AP2013007070A0 (en) * 2011-02-23 2013-08-31 Pfizer Imidazo[5,1-f][1,2,4] triazines for the treatment of neurological disorders
NZ712949A (en) * 2013-05-02 2017-04-28 Pfizer Imidazo-triazine derivatives as pde10 inhibitors

Also Published As

Publication number Publication date
EP2991989A1 (en) 2016-03-09
EP2991989B1 (en) 2017-06-28
US20140329820A1 (en) 2014-11-06
AR096161A1 (es) 2015-12-09
ECSP15050110A (es) 2017-08-31
DOP2015000271A (es) 2016-02-29
ES2637816T3 (es) 2017-10-17
EA201591819A1 (ru) 2016-05-31
WO2014177977A1 (en) 2014-11-06
CN105164134B (zh) 2017-09-22
MX2015015163A (es) 2016-02-22
BR112015027760A8 (pt) 2018-05-08
PH12015502462A1 (en) 2016-02-22
PE20151940A1 (es) 2016-01-21
US9145427B2 (en) 2015-09-29
CN105164134A (zh) 2015-12-16
UA111696C2 (uk) 2016-05-25
US9296761B2 (en) 2016-03-29
TN2015000490A1 (fr) 2017-04-06
AU2014261070A1 (en) 2015-10-29
CR20150591A (es) 2016-01-04
CA2910759C (en) 2018-01-16
UY35547A (es) 2014-11-28
TWI508966B (zh) 2015-11-21
KR101770905B1 (ko) 2017-08-23
US20150080401A1 (en) 2015-03-19
JP6263606B2 (ja) 2018-01-17
ZA201508968B (en) 2017-11-29
JP2016517877A (ja) 2016-06-20
CA2910759A1 (en) 2014-11-06
AP2015008843A0 (en) 2015-11-30
US20150353579A1 (en) 2015-12-10
NZ712949A (en) 2017-04-28
US8933224B2 (en) 2015-01-13
DK2991989T3 (en) 2017-07-31
TW201506027A (zh) 2015-02-16
HK1213885A1 (zh) 2016-07-15
MD20150103A2 (ro) 2016-02-29
SG11201508201VA (en) 2015-11-27
KR20160003234A (ko) 2016-01-08
GEP201706675B (en) 2017-05-25
MA38559B1 (fr) 2018-04-30
EA027936B1 (ru) 2017-09-29
NI201500157A (es) 2015-11-30
CL2015003037A1 (es) 2016-04-22

Similar Documents

Publication Publication Date Title
CO2017011754A2 (es) Amidas heterocíclicas como inhibidores de quinasa
DOP2018000088A (es) Amidas heterocíclicas como inhibidores de cinasas
CR20150470A (es) Derivados de triazolona de piridinilo y piridinilo fusionado
CR20150447A (es) Nuevos derivados de pirazol
CR20150250A (es) Nuevos derivados de piridina
CR20160076A (es) NUEVOS DERIVADOS DE TRIAZOLO[4,5-d]PIRIMIDINA
ECSP15043696A (es) Compuestos de heteroarilo y sus usos
CR20150520A (es) 4-amino-6-(heterocíclico)picolinatos y 6-amino-amino-2-(heterocíclico) pirimidin -4-carboxilatos y su uso como herbicidas
UY35764A (es) El uso de picolinamidas macrociclicas como fungicidas.
CR20140464A (es) Compuestos de heterociclilo
BR112016006366A2 (pt) uso de picolinamidas macrocíclicas como fungicidas
CR20150440A (es) Nuevos derivados de piridina
CR20150061A (es) Compuesto de pirazolopirimidinas
CU20150144A7 (es) Derivados de imidazo-triazina como inhibidores de la pde 10
CR20150204A (es) Nuevos derivados de piridina
DOP2015000059A (es) Amino-quinolinas como inhibidores de cinasa
UY35274A (es) Compuestos y métodos para tratar infecciones bacterianas
CR20160070A (es) Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos
CR20150555A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina
CR20150511A (es) Nuevos derivados de purina
CR20180298A (es) Nuevos derivados de fenilo
EA201400822A1 (ru) Производные гетероциклических амидов в качестве антагонистов p2xрецептора
PE20151145A1 (es) Piridopirazinas sustituidas como inhibidores de syk
UY35236A (es) Compuestos de [1,2,4]triazol e imidazol sustituidos
MX373441B (es) Derivados de indol-urea glucopiranosil-sustituido y su uso como inhibidores sglt.